title: Management of patients with hidradenitis suppurativa.
abstract: Hidradenitis suppurativa (HS) is a chronic inflammatory disease with a high prevalence in the population. Treatment options are both medical and surgical. Medical treatment is based on the use of antibiotics, retinoids, and anti-inflammatory drugs, in which anti-TNFα agents (infliximab y adalimumab) play a central role in the treatment of moderate-to-severe HS and enjoy the highest level of scientific support. Currently, adalimumab is the only drug approved in the summary of product characteristics for the treatment of this disease. Due to the scarcity of clinical trials in HS, there is still no therapeutic guideline backed by solid evidence and the evidence for most drugs is low. However, early treatment in patients with HS would probably reduce the complications of this disease. This review analyses the distinct treatments used in this dermatological disease and provides a therapeutic algorithm with different treatment options.
authors.affiliation: Servicio de Dermatología, Hospital de Manises, Valencia, España. Electronic address: antmarto@hotmail.com.
authors.forename: A
authors.initials: A
authors.lastname: Martorell
authors.affiliation: Servicio de Gastroenterología, Hospital General Universitario Gregorio Marañón, Madrid, España.
authors.forename: A
authors.initials: A
authors.lastname: Caballero
authors.affiliation: Unidad de Enfermedad Inflamatoria Intestinal, Servicio de Aparato Digestivo, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, España.
authors.forename: Y
authors.initials: Y
authors.lastname: González Lama
authors.affiliation: Unidad de Gestión Clínica de Dermatología Médico-Quirúrgica y Venereología, Hospital Universitario Puerta del Mar, Servicio Andaluz de Salud, Cádiz, España.
authors.forename: D
authors.initials: D
authors.lastname: Jiménez-Gallo
authors.affiliation: Servicio de Dermatología, Hospital Universitario Basurto, Bilbao, España.
authors.forename: M
authors.initials: M
authors.lastname: Lázaro Serrano
authors.affiliation: Servicio de Gastroenterología, Hospital General Universitario Gregorio Marañón, Madrid, España.
authors.forename: J
authors.initials: J
authors.lastname: Miranda
authors.affiliation: Servicio de Dermatología, Hospital General de Alicante, Alicante, España.
authors.forename: J C
authors.initials: JC
authors.lastname: Pascual
authors.affiliation: Servicio de Dermatología, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, España.
authors.forename: L
authors.initials: L
authors.lastname: Salgado-Boquete
authors.affiliation: Servicio de Gastroenterología, Hospital General Universitario Gregorio Marañón, Madrid, España.
authors.forename: I
authors.initials: I
authors.lastname: Marín-Jiménez
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use; D000465:Algorithms; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001685:Biological Factors / Q000627:therapeutic use; D019468:Disease Management; D004359:Drug Therapy, Combination; D017497:Hidradenitis Suppurativa / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000150:complications / Q000188:drug therapy; D012176:Retinoids / Q000627:therapeutic use; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D001685:Biological Factors; D006728:Hormones; D007166:Immunosuppressive Agents; D012176:Retinoids; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab
keywords: Adalimumab; Hidradenitis suppurativa; Hidradenitis supurativa; Infliximab; Tratamiento; Treatment